Loading
Saruparib is an experimental DNA-repair inhibitor in advanced trials for selected breast and prostate cancers. It selectively blocks PARP1.
Saruparib selectively inhibits PARP1. PETRA (NCT04644068) is active but not recruiting, with 702 actual participants in its current registry record. A 2026 conference abstract for module 6 of saruparib plus camizestrant reported eight confirmed partial responses among 35 evaluable patients with previously treated ER-positive/HER2-negative breast cancer (22.9%); 38 were treated. Median progression-free survival was 4.4 months (80% CI 2.0-5.6). The nine evaluable BRCA/PALB2-altered patients had a 33.3% response rate; these small, uncontrolled groups do not establish benefit in TNBC. EvoPAR-Breast01 (NCT06380751) is recruiting and selects HR-positive/HER2-negative advanced breast cancer with BRCA1/2 or PALB2 alterations; it is not a TNBC study. Phase 3 prostate studies and a planned HRD-signature-selected phase 2 solid-tumour study expand the pipeline. PARP1 selectivity aims to improve the therapeutic window but does not prove freedom from marrow toxicity.
PARP1-selective inhibitor and trapper (AZD5305). Connects to PARP.
1.Saruparib slips into a pocket on PARP.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Saruparib" OR ABSTRACT:"Saruparib" OR TITLE:"AZD5305" OR ABSTRACT:"AZD5305") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Saruparib, not a curated reading list.
Shares Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors, A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies, PARP, Endometrial cancer and the tag pipeline.
Shares A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs, AstraZeneca, Prostate cancer and the tag pipeline.
Shares Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors, AstraZeneca, Ovarian cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Endometrial cancer, Ovarian cancer, Prostate cancer and the tag pipeline.
Shares Platinum-sensitive ovarian cancer, AstraZeneca, Ovarian cancer and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer, Prostate cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer, Prostate cancer and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer, Prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/